Literature DB >> 24721425

Mitochondrial impairment observed in fibroblasts from South African Parkinson's disease patients with parkin mutations.

Celia van der Merwe1, Ben Loos2, Chrisna Swart3, Craig Kinnear4, Franclo Henning5, Lize van der Merwe6, Komala Pillay7, Nolan Muller8, Dan Zaharie9, Lize Engelbrecht10, Jonathan Carr5, Soraya Bardien3.   

Abstract

Parkinson's disease (PD), defined as a neurodegenerative disorder, is characterized by the loss of dopaminergic neurons in the substantia nigra in the midbrain. Loss-of-function mutations in the parkin gene are a major cause of autosomal recessive, early-onset PD. Parkin has been implicated in the maintenance of healthy mitochondria, although previous studies show conflicting findings regarding mitochondrial abnormalities in fibroblasts from patients harboring parkin-null mutations. The aim of the present study was to determine whether South African PD patients with parkin mutations exhibit evidence for mitochondrial dysfunction. Fibroblasts were cultured from skin biopsies obtained from three patients with homozygous parkin-null mutations, two heterozygous mutation carriers and two wild-type controls. Muscle biopsies were obtained from two of the patients. The muscle fibers showed subtle abnormalities such as slightly swollen mitochondria in focal areas of the fibers and some folding of the sarcolemma. Although no differences in the degree of mitochondrial network branching were found in the fibroblasts, ultrastructural abnormalities were observed including the presence of electron-dense vacuoles. Moreover, decreased ATP levels which are consistent with mitochondrial dysfunction were observed in the patients' fibroblasts compared to controls. Remarkably, these defects did not manifest in one patient, which may be due to possible compensatory mechanisms. These results suggest that parkin-null patients exhibit features of mitochondrial dysfunction. Involvement of mitochondria as a key role player in PD pathogenesis will have important implications for the design of new and more effective therapies.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibroblasts; Mitochondrial dysfunction; Muscle; Parkin mutations; Parkinson’s disease

Mesh:

Substances:

Year:  2014        PMID: 24721425     DOI: 10.1016/j.bbrc.2014.03.151

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Model study of biological effects of weak static magnetic fields at the organismic and subcellular levels.

Authors:  V E Stefanov; B F Shchegolev; O V Kriyachko; N V Kuzmenko; S V Surma; I M Spivak
Journal:  Dokl Biol Sci       Date:  2015-05-05

2.  Mutation of hop-1 and pink-1 attenuates vulnerability of neurotoxicity in C. elegans: the role of mitochondria-associated membrane proteins in Parkinsonism.

Authors:  Siyu Wu; Lili Lei; Yang Song; Mengting Liu; Shibo Lu; Dan Lou; Yonghong Shi; Zhibin Wang; Defu He
Journal:  Exp Neurol       Date:  2018-08-01       Impact factor: 5.330

Review 3.  Mitochondrial dynamism and heart disease: changing shape and shaping change.

Authors:  Gerald W Dorn
Journal:  EMBO Mol Med       Date:  2015-07       Impact factor: 12.137

4.  Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts.

Authors:  Maria C Zanellati; Valentina Monti; Chiara Barzaghi; Chiara Reale; Nardo Nardocci; Alberto Albanese; Enza M Valente; Daniele Ghezzi; Barbara Garavaglia
Journal:  Front Genet       Date:  2015-03-11       Impact factor: 4.599

5.  Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.

Authors:  G A Smith; J Jansson; E M Rocha; T Osborn; P J Hallett; O Isacson
Journal:  Mol Neurobiol       Date:  2015-09-23       Impact factor: 5.590

Review 6.  The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues.

Authors:  Matej Skorvanek; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2016-09-08

Review 7.  Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinson's Disease.

Authors:  Xiao-Le Wang; Si-Tong Feng; Zhen-Zhen Wang; Yu-He Yuan; Nai-Hong Chen; Yi Zhang
Journal:  Cell Mol Neurobiol       Date:  2020-07-04       Impact factor: 5.046

Review 8.  Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First?

Authors:  Michela Zaltieri; Francesca Longhena; Marina Pizzi; Cristina Missale; PierFranco Spano; Arianna Bellucci
Journal:  Parkinsons Dis       Date:  2015-03-31

9.  Altered Mitochondrial Respiration and Other Features of Mitochondrial Function in Parkin-Mutant Fibroblasts from Parkinson's Disease Patients.

Authors:  William Haylett; Chrisna Swart; Francois van der Westhuizen; Hayley van Dyk; Lize van der Merwe; Celia van der Merwe; Ben Loos; Jonathan Carr; Craig Kinnear; Soraya Bardien
Journal:  Parkinsons Dis       Date:  2016-03-08

Review 10.  Roles of PTEN with DNA Repair in Parkinson's Disease.

Authors:  Mako Ogino; Mayuko Ichimura; Noriko Nakano; Akari Minami; Yasuko Kitagishi; Satoru Matsuda
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.